Jim Shannon – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Jim Shannon on 2016-10-17.
To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of slow medicine reimbursement decisions on the level of commercial investment in UK clinical research by companies specialising in rare and ultra-rare conditions.
Nicola Blackwood
Independent evidence suggests that the most important attraction for companies to invest in research in the United Kingdom is the availability of world-class scientific expertise, which is the focus of the Government’s effort to ensure the UK remains at the forefront of global Research and Development. It also suggests that there is no obvious reason why National Health Service reimbursement policy for pharmaceuticals, or the time taken to make decisions on reimbursement, should significantly affect decisions to invest in Research and Development in the UK.
The independently chaired Accelerated Access Review makes recommendations to the Government on reforms to accelerate access for NHS patients to innovative medicines, medical technologies, diagnostics and digital products.
